Skip to main content
Protagenic Therapeutics, Inc.\new logo

Protagenic Therapeutics, Inc.\new — Investor Relations & Filings

Ticker · PTIX ISIN · US74365N2027 LEI · 549300KPBYAVJLPDKB70 US Professional, scientific and technical activities
Open in API
Filings indexed 678 across all filing types
Latest filing 2025-04-18 Declaration of Voting R…
Country US United States of America
Listing US PTIX

About Protagenic Therapeutics, Inc.\new

https://protagenic.com/

Protagenic Therapeutics, Inc. is a biopharmaceutical company focused on developing peptide-based therapeutics for stress-related disorders. The company's core technology is its TCAP (teneurin C-terminal associated peptide) platform, which utilizes neuropeptides to regulate the brain's stress response at a cellular level. This approach aims to counteract the 'Stress Feedback Loop' implicated in various neuropsychiatric and neurodegenerative conditions. Its lead drug candidate, PT00114, a synthetic TCAP, is being developed as a potential first-in-class treatment for disorders such as anxiety and depression.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 18, 2025, for Protagenic Therapeutics, Inc. The key content is the submission of matters to a vote of security holders at a special meeting, specifically the voting results on a reverse stock split proposal and an adjournment proposal. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting. The document is not an annual or quarterly report, nor a proxy solicitation or management discussion. It is a regulatory filing but specifically focused on voting results, so DVA is the most precise classification. The document length is about 4965 characters, which is sufficient to contain detailed voting results rather than just an announcement of a report publication or a brief notice. Therefore, the classification is DVA with high confidence.
2025-04-18 English
Annual Report 2024
Annual Report FY 2024
2025-03-31 English
Proxy Solicitation & Information Statement 2025
Proxy Solicitation & Information Statement
2025-03-07 English
Proxy Solicitation & Information Statement 2025
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a "PRE 14A" form, which is a Preliminary Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is titled "Proxy Statement" and relates to a special meeting of stockholders scheduled for April 18, 2025. The content includes details about proposals to be voted on, voting instructions, and other proxy materials. There is no indication that this is a full annual report, earnings release, or other financial report. Proxy statements are materials sent to shareholders to provide information and solicit votes for meetings. Therefore, this document fits the category of Proxy Solicitation & Information Statement (PSI). The document length is substantial (15,000 characters), indicating it is the statement itself, not just an announcement of its availability. Hence, the classification is PSI with high confidence.
2025-02-27 English
Capital/Financing Update 2025
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. The content focuses on the repricing of stock options approved at the company's 2024 Annual Meeting and subsequent Board action. It reports a specific corporate event related to management and board decisions, specifically about stock option repricing. There are no financial statements or detailed financial performance data present, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a proxy solicitation or voting results announcement. The key content is about changes in the company's board-authorized stock option plans and related management decisions. This fits best under Capital/Financing Update (CAP) because it involves changes to the company's capital structure via stock option repricing. The document length is 4321 characters, which is relatively short but contains substantive information about capital changes, not just an announcement of a report. Therefore, the classification is CAP with high confidence.
2025-02-24 English
Declaration of Voting Results & Voting Rights Announcements 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 21, 2025, by Protagenic Therapeutics, Inc. The key content is the submission of matters to a vote of security holders at the 2024 Annual Meeting of Stockholders. It details the voting results on various proposals including election of directors, approval of stock option repricing, ratification of the independent auditor, and amendments to equity incentive plans. The document is focused on reporting the official results of shareholder votes at the Annual Meeting. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 5738 characters, which is sufficient to contain detailed voting results rather than just an announcement of a report. Therefore, the correct classification is DVA with high confidence.
2025-02-22 English

Browse filings by year

30 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.